Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials

Marcelo C. Pasquini, Brent Logan, Richard J. Jones, Amin M. Alousi, Frederick R. Appelbaum, Javier Bolaños-Meade, Mary E.D. Flowers, Sergio Giralt, Mary M. Horowitz, David Jacobsohn, John Koreth, John E. Levine, Leo Luznik, Richard Maziarz, Adam Mendizabal, Steven Pavletic, Miguel Angel Perales, David Porter, Ran Reshef, Daniel Weisdorf & 1 others Joseph H. Antin

Research output: Contribution to journalArticle

  • 4 Citations

Abstract

Graft-versus-host disease (GVHD) is a common complication after hematopoietic cell transplantation (HCT) and associated with significant morbidity and mortality. Preventing GVHD without chronic therapy or increasing relapse is a desired goal. Here we report a benchmark analysis to evaluate the performance of 6 GVHD prevention strategies tested at single institutions compared with a large multicenter outcomes database as a control. Each intervention was compared with the control for the incidence of acute and chronic GVHD and overall survival and against novel composite endpoints: acute and chronic GVHD, relapse-free survival (GRFS), and chronic GVHD, relapse-free survival (CRFS). Modeling GRFS and CRFS using the benchmark analysis further informed the design of 2 clinical trials testing GVHD prophylaxis interventions. This study demonstrates the potential benefit of using an outcomes database to select promising interventions for multicenter clinical trials and proposes novel composite endpoints for use in GVHD prevention trials.

LanguageEnglish (US)
JournalBiology of Blood and Marrow Transplantation
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Graft vs Host Disease
Bone Marrow
Clinical Trials
Transplants
Recurrence
Benchmarking
Disease-Free Survival
Databases
Cell Transplantation
Multicenter Studies
Morbidity
Mortality
Incidence

Keywords

  • Clinical trials
  • GVHD
  • Hematopoietic cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. / Pasquini, Marcelo C.; Logan, Brent; Jones, Richard J.; Alousi, Amin M.; Appelbaum, Frederick R.; Bolaños-Meade, Javier; Flowers, Mary E.D.; Giralt, Sergio; Horowitz, Mary M.; Jacobsohn, David; Koreth, John; Levine, John E.; Luznik, Leo; Maziarz, Richard; Mendizabal, Adam; Pavletic, Steven; Perales, Miguel Angel; Porter, David; Reshef, Ran; Weisdorf, Daniel; Antin, Joseph H.

In: Biology of Blood and Marrow Transplantation, 01.01.2018.

Research output: Contribution to journalArticle

Pasquini, MC, Logan, B, Jones, RJ, Alousi, AM, Appelbaum, FR, Bolaños-Meade, J, Flowers, MED, Giralt, S, Horowitz, MM, Jacobsohn, D, Koreth, J, Levine, JE, Luznik, L, Maziarz, R, Mendizabal, A, Pavletic, S, Perales, MA, Porter, D, Reshef, R, Weisdorf, D & Antin, JH 2018, 'Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials' Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2018.01.002
Pasquini, Marcelo C. ; Logan, Brent ; Jones, Richard J. ; Alousi, Amin M. ; Appelbaum, Frederick R. ; Bolaños-Meade, Javier ; Flowers, Mary E.D. ; Giralt, Sergio ; Horowitz, Mary M. ; Jacobsohn, David ; Koreth, John ; Levine, John E. ; Luznik, Leo ; Maziarz, Richard ; Mendizabal, Adam ; Pavletic, Steven ; Perales, Miguel Angel ; Porter, David ; Reshef, Ran ; Weisdorf, Daniel ; Antin, Joseph H. / Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. In: Biology of Blood and Marrow Transplantation. 2018.
@article{309c2a4c79bd4085b10b848120da5d7c,
title = "Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials",
abstract = "Graft-versus-host disease (GVHD) is a common complication after hematopoietic cell transplantation (HCT) and associated with significant morbidity and mortality. Preventing GVHD without chronic therapy or increasing relapse is a desired goal. Here we report a benchmark analysis to evaluate the performance of 6 GVHD prevention strategies tested at single institutions compared with a large multicenter outcomes database as a control. Each intervention was compared with the control for the incidence of acute and chronic GVHD and overall survival and against novel composite endpoints: acute and chronic GVHD, relapse-free survival (GRFS), and chronic GVHD, relapse-free survival (CRFS). Modeling GRFS and CRFS using the benchmark analysis further informed the design of 2 clinical trials testing GVHD prophylaxis interventions. This study demonstrates the potential benefit of using an outcomes database to select promising interventions for multicenter clinical trials and proposes novel composite endpoints for use in GVHD prevention trials.",
keywords = "Clinical trials, GVHD, Hematopoietic cell transplantation",
author = "Pasquini, {Marcelo C.} and Brent Logan and Jones, {Richard J.} and Alousi, {Amin M.} and Appelbaum, {Frederick R.} and Javier Bola{\~n}os-Meade and Flowers, {Mary E.D.} and Sergio Giralt and Horowitz, {Mary M.} and David Jacobsohn and John Koreth and Levine, {John E.} and Leo Luznik and Richard Maziarz and Adam Mendizabal and Steven Pavletic and Perales, {Miguel Angel} and David Porter and Ran Reshef and Daniel Weisdorf and Antin, {Joseph H.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2018.01.002",
language = "English (US)",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials

AU - Pasquini, Marcelo C.

AU - Logan, Brent

AU - Jones, Richard J.

AU - Alousi, Amin M.

AU - Appelbaum, Frederick R.

AU - Bolaños-Meade, Javier

AU - Flowers, Mary E.D.

AU - Giralt, Sergio

AU - Horowitz, Mary M.

AU - Jacobsohn, David

AU - Koreth, John

AU - Levine, John E.

AU - Luznik, Leo

AU - Maziarz, Richard

AU - Mendizabal, Adam

AU - Pavletic, Steven

AU - Perales, Miguel Angel

AU - Porter, David

AU - Reshef, Ran

AU - Weisdorf, Daniel

AU - Antin, Joseph H.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Graft-versus-host disease (GVHD) is a common complication after hematopoietic cell transplantation (HCT) and associated with significant morbidity and mortality. Preventing GVHD without chronic therapy or increasing relapse is a desired goal. Here we report a benchmark analysis to evaluate the performance of 6 GVHD prevention strategies tested at single institutions compared with a large multicenter outcomes database as a control. Each intervention was compared with the control for the incidence of acute and chronic GVHD and overall survival and against novel composite endpoints: acute and chronic GVHD, relapse-free survival (GRFS), and chronic GVHD, relapse-free survival (CRFS). Modeling GRFS and CRFS using the benchmark analysis further informed the design of 2 clinical trials testing GVHD prophylaxis interventions. This study demonstrates the potential benefit of using an outcomes database to select promising interventions for multicenter clinical trials and proposes novel composite endpoints for use in GVHD prevention trials.

AB - Graft-versus-host disease (GVHD) is a common complication after hematopoietic cell transplantation (HCT) and associated with significant morbidity and mortality. Preventing GVHD without chronic therapy or increasing relapse is a desired goal. Here we report a benchmark analysis to evaluate the performance of 6 GVHD prevention strategies tested at single institutions compared with a large multicenter outcomes database as a control. Each intervention was compared with the control for the incidence of acute and chronic GVHD and overall survival and against novel composite endpoints: acute and chronic GVHD, relapse-free survival (GRFS), and chronic GVHD, relapse-free survival (CRFS). Modeling GRFS and CRFS using the benchmark analysis further informed the design of 2 clinical trials testing GVHD prophylaxis interventions. This study demonstrates the potential benefit of using an outcomes database to select promising interventions for multicenter clinical trials and proposes novel composite endpoints for use in GVHD prevention trials.

KW - Clinical trials

KW - GVHD

KW - Hematopoietic cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=85041672720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041672720&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2018.01.002

DO - 10.1016/j.bbmt.2018.01.002

M3 - Article

JO - Biology of Blood and Marrow Transplantation

T2 - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -